What are the recent financial highlights of ASTRAZENECA PHARMA IND LT?

ASTRAZENECA PHARMA IND LT recently reported a total revenue of ₹1,619.01 Cr and a net profit margin of 5.99%. These metrics reflect the company’s consistent financial performance.

What is the dividend yield of ASTRAZENECA PHARMA IND LT?

ASTRAZENECA PHARMA IND LT offers a dividend yield of 0.3%, with a dividend rate of ₹24.0 per share.

What are the key financial metrics of ASTRAZENECA PHARMA IND LT?

Key financial metrics include a trailing P/E ratio of 198.62123, forward P/E of , book value of ₹271.705, price-to-book ratio of 28.312326, and a market capitalization of ₹192.42 billion.

What does ASTRAZENECA PHARMA IND LT do?

AstraZeneca Pharma India Limited, a biopharmaceutical company, engages in manufacturing, distributing, and marketing of pharmaceutical products in India and internationally. It manufactures and sells cardiovascular disease, renal, and metabolism medicines under the CRESTOR, Forxiga, BRILINTA, Xigduo, and Seloken XL brand names; oncology medicines under the TAGRISSO, CALQUENCE, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and respiratory medicines under the Symbicort and Fasenra brand names. The company also offers medicines for diabetes and immunology diseases. It also provides clinical trial services. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.

Loading...

₹ 0 0.00%

Loading... BSE: Loding... NSE: Astrazen

About

Loading... ^[1]

Website BSE NSE

Market Cap ₹ 0 Cr.
Current Price ₹ 0
High / Low ₹ 0 / 0
Stock P/E
Dividend Yield 0 %
ROE 0 %
EPS 0
P/B Ratio 0
Net Profit Margin 0 %
Debt to Equity 0
ROCE 0 %
Interest Coverage 0 %

Stock News - Astrazen

Latest updates related to Astrazen

Sr No.	Title	Sentiment
1	HOT STOCKS: ASTRAZEN, ISGEC surge for Profit-Booking; NCC, TANLA Lead Gainers, KIOCL, PHOENIXLTD Face Declines; WELSPUNIND, MANAPPURAM, APARINDS Near Key Moving Averages MarketSmith India	🔄
2	HOT STOCKS: ASTRAZEN, ISGEC surge for Profit-Booking; NCC, TANLA Lead Gainers, KIOCL, PHOENIXLTD Face Declines; WELSPUNIND, MANAPPURAM, APARINDS Near Key Moving Averages MarketSmith India	🔄
3	Stocks in focus: Navin Fluorine International, Fortis Healthcare, AstraZeneca Pharma crossed their 50DEMA levels Upstox	🔄
4	Q4 Results Today: LIC, Natco Pharma, NMDC, Goodyear India, IFB Ind, AstraZeneca among 303 companies to post earnings Mint	🔄
5	Q4 results today: LIC, NMDC, AstraZeneca among 303 firms to post earnings Business Standard	🔄
6	Stock Radar: ONGC, Reliance, PNB, AstraZeneca, GR Infra, BGR Energy, Arkade Developers, Coal India in... Moneycontrol	🔄
7	Asia Deal Watch: AstraZeneca Buys FibroGen’s Chinese Subsidiary Scrip	🔄
8	Stock Radar: ONGC, Reliance, PNB, AstraZeneca, GR Infra, BGR Energy, Arkade Developers, Coal India in... Moneycontrol	🔄
9	AstraZeneca Pharma India (NSE:ASTRAZEN) jumps 6.3% this week, though earnings growth is still tracking behind five-year shareholder returns Simply Wall St	🔄
10	India's AstraZeneca Pharma up on import nod for liver cancer drug TradingView	🔄

Peer Comparison

Macro Industry: Loading.. | Sector: Loading.. | Industry: Loading.. | Basic Industry: Loading..

Loading peers table...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Loading data...

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Loading Profit & Loss data...

Compounded Sales Growth
10 Years:
5 Years:
3 Years:
TTM:

Compounded Profit Growth
10 Years:
5 Years:
3 Years:
TTM:

Stock Price CAGR
10 Years:
5 Years:
3 Years:
1 Year:

Return on Equity
10 Years:
5 Years:
3 Years:
Last Year:

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Shareholding Pattern

Numbers in percentages

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Delivery Data

Insider Data

Technical Data

Static Application Security Testing

Documents

Announcements

Annual reports

Right Issue

Credit ratings

Concalls

Explore More Stocks

RKDL SUNDARMFIN GANESHHOUC SURYALAXMI VINDHYATEL LOKESHMACH RAMCOSYS NECCLTD TATACONSUM SEMAC